Core Viewpoint - Guangyuyuan reported a third-quarter revenue of 281 million yuan, representing a year-on-year increase of 20.31%, while net profit decreased by 82.16% to 2.0269 million yuan [1] Financial Performance - For the third quarter, revenue reached 281 million yuan, up 20.31% year-on-year [1] - Net profit for the third quarter was 2.0269 million yuan, down 82.16% compared to the previous year [1] - For the first three quarters, total revenue was 1.061 billion yuan, reflecting an 18.71% year-on-year growth [1] - Net profit for the first three quarters amounted to 78.884 million yuan, which is an increase of 11.16% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a total revenue of RMB 4.766 billion for Dong'e Ejiao for the nine months ending September 30, 2025, representing a year-on-year growth of 4.41% [1] - The net profit for the same period was RMB 1.277 billion, reflecting a year-on-year increase of 10.77% [1] - As of the announcement date, the company directly holds 10.19% of Dong'e Ejiao's shares and approximately 23.50% through its non-wholly owned subsidiary, indicating a total effective control of about 23.50% [1] Financial Performance - Total revenue for Dong'e Ejiao reached RMB 4.766 billion, up 4.41% year-on-year [1] - Net profit amounted to RMB 1.277 billion, showing a growth of 10.77% compared to the previous year [1] - The cash and cash equivalents at the end of the period were RMB 3.238 billion [1] Ownership Structure - The company directly holds 10.19% of Dong'e Ejiao [1] - Through its subsidiary, China Resources Dong'e Ejiao Co., Ltd., the company holds approximately 23.50% [1] - The total effective control of Dong'e Ejiao by the group is approximately 23.50%, classified as a subsidiary [1]

Core Insights - Taiji Group reported a revenue of 2.43 billion yuan for Q3 2025, representing a year-on-year decline of 7.13% [1] - The net profit attributable to shareholders for Q3 2025 was 27.108 million yuan, down 46.28% year-on-year [1] - For the first three quarters of 2025, the company achieved a total revenue of 8.088 billion yuan, a decrease of 22.49% compared to the previous year [1] - The net profit attributable to shareholders for the first three quarters was 166 million yuan, reflecting a significant decline of 69.56% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 於2025年10月24日，東阿阿膠公佈其截至2025年9月30日止九個月的季度報 告。 東阿阿膠股份有限公司（「東阿阿膠」）為一家於中華人民共和國註冊成立的 公司。東阿阿膠的股份於深圳證券交易所上市。截至本公告日期，東阿阿膠 由華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）直接 持有10.19%股權，通過本公司非全資附屬公司華潤東阿阿膠有限公司持有約 23.50%，本集團實際控制東阿阿膠約23.50%並入賬為本公司的附屬公司。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 東阿阿膠 截至2025年9月30日止九個月的未經審核財務業績 東阿阿膠未經審核財務資料乃根據中國公認會計準則編製，且未經本公司核 數師審閱或審核，在審核過程中可能須予調整。有關財務資料僅限於東阿阿 膠，並不能全面反映本集團的營運或財務狀況。股東及潛在投資者買賣本公 司證券時務請僅慎行事，且不應完全依 ...

Core Viewpoint - Dong'e Ejiao (000423) reported a positive growth in both revenue and net profit for the third quarter of 2025, indicating a strong performance in the market [1] Financial Performance - In Q3 2025, the company achieved a revenue of 1.716 billion yuan, representing a year-on-year increase of 8.5% [1] - The net profit attributable to shareholders for Q3 2025 was 456 million yuan, showing a year-on-year growth of 10.27% [1] - For the first three quarters of 2025, the total revenue reached 4.766 billion yuan, with a year-on-year increase of 4.41% [1] - The net profit attributable to shareholders for the first three quarters was 1.274 billion yuan, reflecting a year-on-year growth of 10.53% [1]

Core Insights - Dong-E-E-Jiao reported a revenue of 1.716 billion yuan for Q3 2025, representing a year-on-year growth of 8.50% [1] - The net profit attributable to shareholders for Q3 2025 was 456 million yuan, showing a year-on-year increase of 10.27% [1] - For the first three quarters of 2025, the company achieved a total revenue of 4.766 billion yuan, which is a 4.41% increase compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 1.274 billion yuan, reflecting a year-on-year growth of 10.53% [1]

东阿阿胶公告，第三季度营收为17.16亿元，同比增长8.50%；净利润为4.56亿元，同比增长10.27%。前 三季度营收为47.66亿元，同比增长4.41%；净利润为12.74亿元，同比增长10.53%。 ...

Core Viewpoint - The company reported a significant decline in revenue for the third quarter, indicating potential challenges in its operational performance [1] Financial Performance - The third quarter revenue was 151 million yuan, a year-on-year decrease of 34.63% [1] - The net profit for the third quarter was a loss of 926,700 yuan [1] - For the first three quarters, the total revenue was 647 million yuan, reflecting a year-on-year decline of 16.12% [1] - The net profit for the first three quarters was 27.03 million yuan, which represents a year-on-year increase of 8.11% [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.56% on October 24, with Zhen Dong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Nonghui Co., Ltd. (603139) with a closing price of 22.86, up 1.87% [1] - Tianmu Pharmaceutical (600671) at 19.28, up 1.80% [1] - Huasen Pharmaceutical (002907) at 17.14, up 1.48% [1] - Major decliners included: - Zhen Dong Pharmaceutical (300158) at 6.93, down 5.33% [2] - Qidi Pharmaceutical (000590) at 12.23, down 3.55% [2] - Zhongsheng Pharmaceutical (002317) at 17.96, down 2.55% [2] Capital Flow - The Chinese medicine sector saw a net outflow of 577 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2] - The sector's capital flow indicated a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Key stocks with significant capital flow included: - China Resources Sanjiu (6660000) with a net inflow of 17.64 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 14.57 million yuan [3] - Yunnan Baiyao (000538) with a net inflow of 12.11 million yuan [3] - Conversely, stocks like Huasen Pharmaceutical (002907) experienced a net outflow of 11.31 million yuan from retail investors [3]

Core Insights - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters, representing a year-on-year growth of 10.10% [1] - The net profit reached 1.274 billion yuan, with a year-on-year increase of 10.58% [1] - The company's gross profit margin stands at 73.69%, indicating a stable growth in its core product matrix [1] Business Strategy - Dong'e Ejiao is actively expanding into the silver economy and men's health sectors, indicating a strategic diversification of its product offerings [1] - The company is accelerating its overseas business expansion, enhancing its competitive edge in the traditional Chinese medicine health sector [1] - The overall comprehensive competitiveness and long-term investment value of Dong'e Ejiao in the health industry are further improved [1]